Objectives: To assess therapeutic levels, safety and tolerability of a novel formulation SUBA-itraconazole (where SUBA stands for SUper BioAvailability) when compared with conventional itraconazole liquid when used as antifungal prophylaxis in patients undergoing allogeneic HSCT or in haematological malignancy patients with an intermediate/high risk of invasive fungal infection (IFI).
Introduction
Invasive fungal infections (IFIs) in patients with haematological malignancies and those undergoing HSCT are associated with significant morbidity, mortality and cost to the health care system. 1, 2 Antifungal prophylaxis has an established role in prevention of IFI, though individual choice of agent and the precise indications for antifungal prophylaxis remain unclear. 3 The decision to use antifungal prophylaxis must take into account local prevalence and infection patterns and toxicities of individual agents, as well as cost and availability. When assessing the benefit and costeffectiveness of antifungal prophylaxis, numbers needed to treat (NNT) as well as numbers needed to harm (NNTH), together with an individual patient's IFI risk, need to be considered before a decision is made to institute IFI prophyalxis. 4, 5 Whilst fluconazole is a suitable IFI prophylactic agent for patients at low, short-term risk, 5 for those at intermediate or high risk, where Aspergillus species and other moulds are important IFI pathogens, a mould-active agent such as posaconazole, itraconazole, voriconazole, isavuconazole or an echinocandin is required. While the efficacy of some of these agents as IFI prophylaxis has been established through randomized trials, each has its limitations. The newer agents such as isavuconazole and posaconazole are high-cost drugs and are not cost-effective in some low-risk groups, echinocandins are only available as intravenous preparations, voriconazole has a narrow therapeutic window, a high incidence of side effects and variable pharmacokinetics, and conventional itraconazole has been limited by variable bioavailability and poor tolerability of the liquid suspension. 6 Pharmacokinetic variability due to inconsistent absorption, metabolism, elimination or interaction with concomitant medications has been demonstrated for the triazole antifungal drugs posaconazole, itraconazole and voriconazole, mandating therapeutic drug monitoring (TDM) to optimize drug choice and dosing. 7 In early trials of antifungal prophylaxis using these agents, TDM was not always performed, preventing accurate extrapolation of results to clinical practice. This is particularly relevant in early itraconazole trials, when either no TDM or only limited TDM was performed despite the drug having highly variable pharmacokinetics. 6, 8 Itraconazole is an orally administered broad-spectrum triazole antifungal, used for both prophylaxis and treatment of systemic fungal infections.
9,10 Both itraconazole and its major active metabolite, hydroxyitraconazole, exert antifungal activity through the inhibition of fungal cytochrome P450 (CYP) 3A isoenzymes, which mediate the synthesis of ergosterol, a vital component of the fungal cell membrane.
11
To address the limited bioavailability and intolerance of the conventional itraconazole formulation, a new formulation, labelled SUBA-itraconazole (where SUBA stands for SUper BioAvailability), has been developed by Mayne Pharmaceuticals (Salisbury, South Australia) with the brand name Lozanoc. Initial studies of the SUBA-itraconazole formulation in healthy subjects have demonstrated superior relative bioavailability of 173% compared with conventional capsules and 21% less interpatient variability. 10 In addition, the SUBA-itraconazole formulation is in capsule form, which improves gastrointestinal tolerability compared with the conventional liquid formulation.
This prospective comparative cohort study was designed to assess the time to achieve therapeutic levels of SUBA-itraconazole compared with a retrospective control group receiving conventional itraconazole liquid formulation when used as IFI prophylaxis in patients undergoing allogeneic HSCT or in patients considered to have an intermediate/high risk of IFI associated with treatment of a haematological malignancy. Efficacy and tolerability of treatment in both groups were also assessed.
Methods

Study design
This study was an investigator-initiated, prospective comparative cohort study. The study was conducted at a single tertiary referral hospital in Sydney, Australia, between February 2014 and August 2016. Ethics approval was obtained from the North Sydney Local Health District Human Research Ethics Committee (LNR/16/HAWKE/205).
In the experimental group SUBA-itraconazole was given at an initial dose of 200 mg (4%50 mg capsules) twice daily, on an empty stomach, half an hour before food. Trough plasma concentrations were measured twice weekly throughout the study period. If trough concentrations were .2000 ng/mL, the dose was reduced by 50 mg/dose every week until steadystate concentrations returned to ,2000 ng/mL. If the patient was unable to swallow capsules due to mucositis or swallowing difficulties, the contents of the opened capsule were dispersed in thickened fluid for administration.
The historical control group was given liquid itraconazole at an initial dose of 200 mg (20 mL) twice daily, on an empty stomach, half an hour before food. Trough plasma concentrations and dose adjustments were the same as in the SUBA-itraconazole group.
In the HSCT group, itraconazole was initiated from day !1 of the transplant and continued throughout the duration of immunosuppression, approximately until day !100 in the absence of graft-versus-host disease (GVHD). In the high/intermediate-risk IFI group with haematological malignancy, itraconazole was initiated when patients became neutropenic (,0.5%10 9 /L) and was continued until neutrophil recovery. This study assessed outcomes in the first 30 days following the initiation of standard or SUBA-itraconazole. Patients were excluded if they were on a treatment course of another antifungal drug for a recent IFI prior to transplant.
Patients
All consecutive patients who underwent an allogeneic HSCT were included in the study. In addition, all consecutive patients who had a haematological malignancy and were considered to have an intermediate or high risk of IFI defined by neutropenia 0.1-0.5%10 9 /L for 3-5 weeks, ALL, AML, corticosteroids .1 mg/kg prednisolone equivalent and neutrophils ,1%10 9 /L for .1 week, or corticosteroids .2 mg/kg prednisolone equivalent for .2 weeks (adapted from the 2014 Australian consensus guidelines for antifungal prophylaxis in haematological malignancy and HSCT) 5 and did not fulfil eligibility criteria for posaconazole or voriconazole in the Australian National Pharmaceutical Benefits Scheme [therefore, excluding AML, myelodysplastic syndrome (MDS) and acute or chronic GVHD patients] 12 were also included in the study. The SUBA-itraconazole cohort was prospectively assessed between April 2015 and June 2016. The historical control cohort consisted of all patients treated from February 2014 to March 2015 using the same inclusion and exclusion criteria.
Pharmacokinetics
Plasma itraconazole concentrations were measured twice weekly from initiation of therapy using a previously validated HPLC-UV assay as part of standard of care, and target trough concentrations for prophylactic efficacy were defined as .500 ng/mL. 13 Drug concentrations were assessed for mean trough concentrations at steady-state from after 14 days of therapy, based on previous studies. The coefficient of variation (CV) was calculated to describe interpatient variability.
Safety and tolerability
Clinical and radiological monitoring for IFI was undertaken throughout the study period as part of standard clinical practice, or as prompted by neutropenic fever .96 h not responding to empirical antibiotic therapy. Possible or probable IFI was defined by established EORTC/MSG criteria.
14 Regular liver function tests (LFTs) were performed to assess drug-attributable hepatotoxicity; if moderate to severe toxicity was seen [defined as Drug-Induced Liver Injury Network (DILIN) grade 3! liver injury with raised serum aminotransferase or alkaline phosphatase levels and total serum bilirubin level .2.5 mg/dL] 15 itraconazole was ceased and an alternative antifungal agent was initiated. Mild to moderate liver dysfunction did not mandate cessation of the drug. Nausea or other gastrointestinal intolerance was attributed to itraconazole if the patient developed symptoms after taking the dose, despite prophylactic anti-emetics; if the patient continued to be intolerant to the itraconazole after the addition of breakthrough antiemetics, another antifungal agent was substituted intravenously.
Secondary outcomes, efficacy and treatment failure
Patients were considered treatment failures and were changed to an alternative antifungal agent if they failed to obtain therapeutic levels after 14 days of therapy, were intolerant to therapy, or developed a probable or possible IFI defined by the EORTC/MSG criteria. 13 SUBA-itraconazole in allogeneic stem cell transplantation and haematological malignancy
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Statistical analyses
Patient characteristics were compared between groups using a t-test or v 2 test as appropriate. The cumulative incidence of patients attaining therapeutic targets was calculated using the Kaplan-Meier method and the curves were compared using the log-rank test. Analyses were performed in R 3.3.1 using the OIsurv for survival analysis. 16 Day 100 and overall survival analysis was estimated by the Kaplan-Meier method, and survival outcomes compared by Cox regression analysis.
Results
Patients
A total of 57 patients were assessed: 27 in the SUBA-itraconazole cohort and 30 in the liquid itraconazole cohort. SUBA-itraconazole patients and the historical control group were well matched with respect to age, sex and indication for antifungal administration (characteristics are summarized in Table 1 ). Overall survival for liquid itraconazole versus SUBA-itraconazole using a day 100 landmark analysis was not significantly different (90.0% versus 88.9%) (P " 0.29). The 3 year overall survival estimate for the entire cohort was 75.4%. Over the study period a total of 336 serum itraconazole levels were taken: 173 for SUBA-itraconazole and 163 for liquid itraconazole.
Pharmacokinetics
Therapeutic concentrations were achieved significantly more quickly in the SUBA-itraconazole group. In the SUBA-itraconazole cohort, therapeutic levels were achieved at a median of 6 (95% CI 5-11) days versus 14 (95% CI 12-21) days in the liquid itraconazole group (P , 0.0001). At day 10, therapeutic concentrations were achieved in 69% (95% CI 44%-81%) of the SUBA-itraconazole group versus 21% (95% CI 7%-33%) in the liquid itraconazole group (P , 0.0001) (Figure 1 ). The mean trough serum concentrations at steady-state of SUBA-itraconazole were significantly higher, with less interpatient variability (1577 ng/mL, CV 35%) compared with the liquid itraconazole formulation (1218 ng/mL, CV 60%) (P , 0.001) (Figure 2 ). All levels are documented in Figure S1 and Tables S1 and S2 (available as Supplementary data at JAC Online). More patients required dose reductions in the SUBA-itraconazole group [52% (14/27) versus 20% (6/30) (P , 0.01) in the liquid itraconazole cohort] because of supratherapeutic levels. In the SUBA-itraconazole group there did not appear to be any difference in the number of patients requiring dose reduction between the haematological malignancy group (40%, 2/5) and the HSCT group (55%, 12/22) (P " 0.62), though small numbers limit the utility of this analysis. By day 30 the median SUBA-itraconazole dose required was 150 mg (range 50-200 mg) twice daily.
Safety and tolerability
There were two (7.4%) treatment failures in the SUBA-itraconazole group, both due to cessation of therapy for grade 4 mucositis requiring intravenous agents; one patient ceased therapy prior to attaining therapeutic levels and the other attained therapeutic levels prior to cessation. There were seven (23.3%) treatment failures in the liquid itraconazole group: five due to cessation of therapy for subtherapeutic levels after 14 days, one due to grade 4 mucositis requiring an intravenous agent and one due to gastrointestinal intolerance. Although this result was not significant, there was a trend in favour of SUBA-itraconazole (P " 0.096). Three patients in the SUBA-itraconazole and eight patients in the liquid itraconazole group developed mild LFT derangement (DILIN grade 1!), while two patients in the liquid itraconazole group developed moderate Lindsay et al.
raised bilirubin (.2.5 mg/dL, DILIN grade 2!). No treatment was ceased for LFT abnormalities and all patients normalized LFT abnormalities despite ongoing administration of itraconazole during the study period. Consequently, the transient LFT derangements in these patients, all of whom were HSCT recipients, were attributed to conditioning chemotherapy. No other commonly reported adverse effects attributable to itraconazole, including signs and symptoms of heart failure, hearing loss or neuropathy were observed during the study period.
There was one probable IFI in the liquid itraconazole treatment failure group, defined by radiological evidence of a dense, wellcircumscribed lesion with a halo sign on CT scanning of the chest on day 19 after commencing itraconazole. This episode was associated with day 13 itraconazole levels that were subtherapeutic (55 ng/mL). Therapy was changed to intravenous posaconazole and the patient made a full recovery. There was also one confirmed IFI in the SUBA-itraconazole treatment failure group defined by a blood culture that yielded yeast; however, this was after the cessation of SUBA-itraconazole for mucositis and prior to attaining therapeutic levels of intravenous posaconazole. Figure 1 . Target attainment (.500 ng/mL) by itraconazole formulation (P , 0.0001). SUBA-itraconazole on the left, with a 50% probability at day 6; liquid itraconazole on the right, with a 50% probability at day 13. SUBA-itraconazole in allogeneic stem cell transplantation and haematological malignancy JAC and poor gastrointestinal tolerability, and more recently by the increasing availability of newer agents. 8, 17, 18 The results of this study have demonstrated that the SUBAitraconazole formulation was associated with more rapid attainment of therapeutic levels with less interpatient variability compared with conventional liquid itraconazole. In addition, because SUBA-itraconazole is a capsule, gastrointestinal tolerability compared with conventional liquid itraconazole was improved, with no patients in the SUBA-itraconazole group failing therapy due to gastrointestinal toxicity.
Our study suggests that SUBA-itraconazole has a superior pharmacokinetic profile compared with liquid itraconazole when used as a mould-active prophylactic agent in allogeneic HSCT and intermediate-or high-IFI-risk patients. With a local cost approximately one-third of that of voriconazole and one-fifth of posaconazole there is the potential for improved cost-effectiveness when considering the NNT based on an individual patient's IFI risk. 12 In addition, although TDM is still required, as for most antifungal prophylactic agents, more rapid attainment of therapeutic levels and less interpatient variability may reduce the need for frequent TDM when using SUBA-itraconazole. Indeed, the two cases of IFI reported in this study highlight the importance of TDM when using itraconazole since both occurred at times when itraconazole levels were subtherapeutic.
Fifty-two percent of patients in the SUBA-itraconazole cohort and 20% of patients in the itraconazole cohort required dose reductions due to supratherapeutic levels of itraconazole. Not unusually in this clinical setting, many patients were administered concomitant medications with the potential for interaction with itraconazole, the most significant being cyclosporine, a CYP4503A4 inhibitor, 19 in the HSCT group. In addition, itraconazole is itself a strong 3A4 inhibitor, inhibiting its own metabolism as it reaches steady-state. This again highlights the importance of TDM, particularly when using the SUBA preparation, in order to avoid supratherapeutic levels and potential toxicity that may be associated with the improved bioavailability of SUBA-itraconazole.
To date, studies of IFI prophylaxis in the post-allogeneic setting have favoured mould-active agents other than conventional liquid itraconazole. The largest randomized controlled trial in this setting was conducted by Marks et al. 17 (n " 489) comparing voriconazole with conventional liquid itraconazole. A composite endpoint, which included the ability to tolerate study drug for at least 100 days, with 14 days interruption and survival without proven/probable IFI to day 180, favoured the voriconazole arm (48.7% versus 33.2%) (P , 0.01), but the study could not demonstrate a survival difference (81.9% versus 80.9%) or difference in proven/probable IFI rate (1.3% versus 2.1%) between the voriconazole and itraconazole arms, respectively. 17 In this study, serum levels were available in 53.9% of patients in the itraconazole arm, with only 10% of patients having median trough itraconazole concentrations of 0.89 (0-2.46) lg/mL. Of the investigator-reported discontinuations in the liquid itraconazole arm, 24.8% were due to gastrointestinal intolerance versus 1.9% in the voriconazole arm. Sá nchez-Ortega et al. 20 compared the efficacy of posaconazole as IFI prophylaxis in the post-allogeneic setting (n " 33) versus a historical control of patients receiving liquid and/or intravenous itraconazole (n " 16) in a single-centre study. This study demonstrated a lower cumulative incidence of proven or probable IFI (0% versus 12%) (P " 0.04) together with improved probability of fungal-free (91% versus 56%) (P " 0.04) and overall survival (91% versus 63%) (P " 0.011) in the more recent cohort receiving posaconazole. However, the findings of the study were limited by its observational nature, differences in transplant regimens, disease groups and clinical practice over time as well as a lack of TDM. 20 In the setting of haematological malignancy, Cornely et al. 21 conducted a landmark randomized controlled trial (n " 304) of IFI prophylaxis in neutropenic AML or MDS patients, a group specifically excluded from our study. This study compared posaconazole with a control arm of itraconazole liquid or the mould-inactive agent fluconazole. Proven or probable IFIs were reported in 2% of the posaconazole group versus 8% of the fluconazole or itraconazole group (P , 0.001) and survival was significantly longer among recipients of posaconazole than among recipients of fluconazole or itraconazole (P " 0.04). However, the outcomes of the study compared fluconazole and itraconazole liquid together, with no subgroup analysis of itraconazole liquid alone. In addition, TDM was only conducted in 56% of itraconazole patients and gastrointestinal symptoms were more frequently reported than in patients receiving fluconazole or posaconazole. These studies suggest that the inferior outcomes associated with itraconazole may, at least in part, be overcome with the use of a bettertolerated preparation, improved bioavailability and appropriately managed TDM.
Small numbers and the single-centre nature of our report limit the widespread applicability of our findings. In addition, the comparative nature of our study means that it is possible that other changes in clinical practice may have had an impact over time. However, there were no significant differences between the cohorts that may have explained the superior tolerability or bioavailability of the SUBA-itraconazole product and the observed rate of breakthrough IFI in this study, which was not significantly different between our two cohorts and was similar to previous studies that have reported the use of both conventional itraconazole and voriconazole as primary prophylaxis post allogeneic transplantation. 17 This study has demonstrated that the SUBA-itraconazole formulation is associated with more rapid attainment of therapeutic levels with less interpatient variability when compared with conventional liquid itraconazole. Clearly, individual practice must be informed by local fungal prevalence and infection patterns, costeffectiveness and toxicity profiles of individual agents. Future randomized trials will be necessary to determine the exact role of the SUBA-itraconazole preparation when compared with currently accepted alternative mould-active agents as IFI prophylaxis in settings where itraconazole may be considered as a reasonable alternative in patients with an intermediate to high risk of fungal infection.
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